Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Mar 7;11:67. doi: 10.3389/fncel.2017.00067

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Yu, Wang, Zhao, Zhang, Tao, Shi, Sun and Ding.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Involvement of ERK pathway in the neuroprotection of NaHS. (A,B) OGD treatment inhibited p-ERK1/2 (MW: p-ERK1/2, 44/42 kDa; EKR1/2, 44/42 kDa) expression in both young and aged hippocampal neurons, while 250 μM NaHS could increase ERK1/2 phosphorylation, characterized by western blot analysis. (C,D) Western blotting shows that there was no significant difference in PKA (MW: 45 kDa) levels between the experimental groups. (E,F) OGD increased PP2A (MW: 35 kDa) expressions, while NaHS decreased its expressions. The expression levels from each group were normalized to those of GAPDH (as a loading control, MW: 37 kDa) and are presented as ratios to control. Data were presented by mean ± SD. ^∗p < 0.05 and ^∗∗p < 0.01 versus corresponding control (no treatment), ^##p < 0.01 versus corresponding OGD group.